New biotechnology combines targeted and immune therapies to kill treatment-resistant cancer cells



New biotechnology combines targeted and immune therapies to kill treatment-resistant cancer cells

Researchers harnessed a natural system, the major histocompatibility complexes (MHCs), to take targeted drugs — only when attached to their protein targets inside cancer cells — and display them on the surfaces of those cells. There the combinations flagged down antibodies designed by the team to label cancer cells for destruction by T cells.

Materials provided by NYU Langone Health / NYU Grossman School of Medicine. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

18th March 2023

New combination of drugs works together to reduce lung tumors in mice

Read more
17th March 2023

Study offers a potential strategy to improve T cell therapy in solid tumors

Read more
17th March 2023

Researchers chart a course for understanding, preventing, and treating young-onset colorectal cancer

Read more